Literature DB >> 12007508

Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases.

T Papadaki1, K Stamatopoulos, N Stavroyianni, G Paterakis, M Phisphis, K Stefanoudaki-Sofianatou.   

Abstract

We report two cases with B cell malignancies (case #1: refractory mantle cell lymphoma; case #2: lymphocyte predominant Hodgkin's disease (LPHD)) who developed neutropenia post-Rituximab therapy in a setting of significant infiltration of the peripheral blood (PB) and bone marrow (BM) by T cells with an immunophenotype of large granular lymphocytes. Possible pathogenetic mechanisms are discussed.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12007508     DOI： 10.1016/s0145-2126(01)00183-7

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  12 in total

Review 1.  Rituximab-associated neutropenia.

Authors:  Kieron Dunleavy; Kevin Tay; Wyndham H Wilson
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

2.  Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma.

Authors:  Kenji Fukuno; Hisashi Tsurumi; Nobuhiro Ando; Nobuhiro Kanemura; Hideko Goto; Shinobu Tanabashi; Kiyonao Okamoto; Hisataka Moriwaki
Journal:  Int J Hematol       Date:  2006-10       Impact factor: 2.490

3.  Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.

Authors:  Wen-Kai Weng; Robert S Negrin; Philip Lavori; Sandra J Horning
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

4.  Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis.

Authors:  Daniel Tesfa; Tobias Gelius; Birgitta Sander; Eva Kimby; Bengt Fadeel; Jan Palmblad; Hans Hägglund
Journal:  Med Oncol       Date:  2008-02-16       Impact factor: 3.064

Review 5.  The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders.

Authors:  Ranran Zhang; Mithun Vinod Shah; Thomas P Loughran
Journal:  Hematol Oncol       Date:  2010-09       Impact factor: 5.271

6.  Rituximab-related late-onset neutropenia in patients with rheumatic diseases: successful re-challenge of the treatment.

Authors:  Tatiana Reitblat; Alexander Wechsler; Olga Reitblat
Journal:  Am J Case Rep       Date:  2015-04-09

Review 7.  Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.

Authors:  Brian A Baldo
Journal:  Oncoimmunology       Date:  2013-10-17       Impact factor: 8.110

8.  Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease.

Authors:  Reza Zonozi; Zachary S Wallace; Karen Laliberte; Noah R Huizenga; Jillian M Rosenthal; Eugene P Rhee; Frank B Cortazar; John L Niles
Journal:  Arthritis Rheumatol       Date:  2020-12-29       Impact factor: 10.995

9.  Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone.

Authors:  Evgeniy Evdoshenko; Alexey Maslyanskiy; Sergey Lapin; Leonid Zaslavsky; Ruth Dobson; Areg Totolian; Alexander Skoromets; Amit Bar-Or
Journal:  ISRN Neurol       Date:  2013-09-10

10.  Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry.

Authors:  J H Salmon; P Cacoub; B Combe; J Sibilia; B Pallot-Prades; O Fain; A Cantagrel; M Dougados; E Andres; O Meyer; P Carli; E Pertuiset; I Pane; F Maurier; P Ravaud; X Mariette; J E Gottenberg
Journal:  RMD Open       Date:  2015-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.